Assessing Patient Confidence With Biosimilars

Panelists discuss how health care professionals have varying confidence in biosimilars, driven by concerns about efficacy, safety, and interchangeability. Increased education, real-world evidence, professional engagement, transparent regulations, and comprehensive outcome data can help build trust in these alternative biologic treatments.

EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability

EP: 2.The Economic Impact of Biosimilars

EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars

EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars

EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption

EP: 6.Positioning Biosimilars in Clinical Practice

Now Viewing

EP: 7.Assessing Patient Confidence With Biosimilars

EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars

EP: 9.The Growing Market for Biosimilars

EP: 10.Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models

EP: 11.The Biosimilar Shift: How PBMs Are Reshaping Formularies

EP: 12.The Road to Biosimilar Adoption: Navigating Interchangeability

EP: 13.How the IRA is Reshaping Biosimilar Adoption

EP: 14.Cost Savings Potential Associated With the Use of Biosimilars

EP: 15.Examining the Role of Interchangeability in Clinical Practice

EP: 16.Optimizing the Implementation of Biosimilars Into Formularies

EP: 17.Key Pearls for Collaborating With Manufacturers for Successful Uptake of Biosimilars

EP: 18.Working With Policy Makers to Effectively Implement Biosimilars

Video content above is prompted by the following:

• How do you view patient confidence with biosimilars so far? What can be done to increase their confidence in biosimilars?

Related Videos

Related Content

Advertisement

Published: July 29th 2025 | Updated: July 29th 2025

Adalimumab, Etanercept Biosimilars Deliver Real-World Results for Juvenile Idiopathic Arthritis

Hayden E. Klein

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts.

July 29th 2025

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

Skylar Jeremias Hillel P. Cohen, PhD Giuseppe Randazzo

July 29th 2025

FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older

Brooke McCormick

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 28th 2025

Pediatric Hypertension Increasing Among Children, Adolescents Worldwide

Brooke McCormick

This global study found rising rates of pediatric hypertension, highlighting obesity's impact and the need for improved monitoring and prevention strategies.

July 28th 2025

Long COVID More Common Among Socially Vulnerable Individuals

Brooke McCormick

Social risk factors significantly increase the likelihood of developing long COVID, highlighting the urgent need for equitable health care and support systems.

Related Content

Advertisement

Published: July 29th 2025 | Updated: July 29th 2025

Adalimumab, Etanercept Biosimilars Deliver Real-World Results for Juvenile Idiopathic Arthritis

Hayden E. Klein

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts.

July 29th 2025

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

Skylar Jeremias Hillel P. Cohen, PhD Giuseppe Randazzo

July 29th 2025

FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older

Brooke McCormick

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 28th 2025

Pediatric Hypertension Increasing Among Children, Adolescents Worldwide

Brooke McCormick

This global study found rising rates of pediatric hypertension, highlighting obesity's impact and the need for improved monitoring and prevention strategies.

July 28th 2025

Long COVID More Common Among Socially Vulnerable Individuals

Brooke McCormick

Social risk factors significantly increase the likelihood of developing long COVID, highlighting the urgent need for equitable health care and support systems.